These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 20006333)

  • 21. A novel mutation in proprotein convertase subtilisin/kexin type 9 gene leads to familial hypercholesterolemia in a Chinese family.
    Lin J; Wang LY; Liu S; Wang XM; Yong Q; Yang Y; DU LP; Pan XD; Wang X; Jiang ZS
    Chin Med J (Engl); 2010 May; 123(9):1133-8. PubMed ID: 20529551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy.
    Raal F; Panz V; Immelman A; Pilcher G
    J Am Heart Assoc; 2013 Apr; 2(2):e000028. PubMed ID: 23537802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The molecular basis of familial hypercholesterolemia in Lebanon: spectrum of LDLR mutations and role of PCSK9 as a modifier gene.
    Abifadel M; Rabès JP; Jambart S; Halaby G; Gannagé-Yared MH; Sarkis A; Beaino G; Varret M; Salem N; Corbani S; Aydénian H; Junien C; Munnich A; Boileau C
    Hum Mutat; 2009 Jul; 30(7):E682-91. PubMed ID: 19319977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome.
    Sjouke B; Kusters DM; Kindt I; Besseling J; Defesche JC; Sijbrands EJ; Roeters van Lennep JE; Stalenhoef AF; Wiegman A; de Graaf J; Fouchier SW; Kastelein JJ; Hovingh GK
    Eur Heart J; 2015 Mar; 36(9):560-5. PubMed ID: 24585268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture.
    Mayne J; Dewpura T; Raymond A; Bernier L; Cousins M; Ooi TC; Davignon J; Seidah NG; Mbikay M; Chrétien M
    Clin Chem; 2011 Oct; 57(10):1415-23. PubMed ID: 21813713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations.
    Futema M; Plagnol V; Li K; Whittall RA; Neil HA; Seed M; ; Bertolini S; Calandra S; Descamps OS; Graham CA; Hegele RA; Karpe F; Durst R; Leitersdorf E; Lench N; Nair DR; Soran H; Van Bockxmeer FM; ; Humphries SE
    J Med Genet; 2014 Aug; 51(8):537-44. PubMed ID: 24987033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic analysis of familial hypercholesterolaemia in Western Australia.
    Hooper AJ; Nguyen LT; Burnett JR; Bates TR; Bell DA; Redgrave TG; Watts GF; van Bockxmeer FM
    Atherosclerosis; 2012 Oct; 224(2):430-4. PubMed ID: 22883975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The genetic spectrum of familial hypercholesterolemia in Pakistan.
    Ahmed W; Whittall R; Riaz M; Ajmal M; Sadeque A; Ayub H; Qamar R; Humphries SE
    Clin Chim Acta; 2013 Jun; 421():219-25. PubMed ID: 23535506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of LDLR and PCSK9 pathogenic variants in Japanese heterozygous familial hypercholesterolemia patients.
    Hori M; Ohta N; Takahashi A; Masuda H; Isoda R; Yamamoto S; Son C; Ogura M; Hosoda K; Miyamoto Y; Harada-Shiba M
    Atherosclerosis; 2019 Oct; 289():101-108. PubMed ID: 31491741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LDLR promoter variant and exon 14 mutation on the same chromosome are associated with an unusually severe FH phenotype and treatment resistance.
    Snozek CL; Lagerstedt SA; Khoo TK; Rubenfire M; Isley WL; Train LJ; Baudhuin LM
    Eur J Hum Genet; 2009 Jan; 17(1):85-90. PubMed ID: 18648394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PCSK9 and LDL cholesterol: unravelling the target to design the bullet.
    Costet P; Krempf M; Cariou B
    Trends Biochem Sci; 2008 Sep; 33(9):426-34. PubMed ID: 18672372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Degradation of LDLR protein mediated by 'gain of function' PCSK9 mutants in normal and ARH cells.
    Fasano T; Sun XM; Patel DD; Soutar AK
    Atherosclerosis; 2009 Mar; 203(1):166-71. PubMed ID: 19081568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional Characterization of p.(Arg160Gln) PCSK9 Variant Accidentally Found in a Hypercholesterolemic Subject.
    Larrea-Sebal A; Trenti C; Jebari-Benslaiman S; Bertolini S; Calandra S; Negri EA; Bonelli E; Benito-Vicente A; Uraga-Gracianteparaluceta L; Martín C; Fasano T
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of a splice site mutation in LDLR gene and two variations in PCSK9 gene in Tunisian families with familial hypercholesterolaemia.
    Jelassi A; Slimani A; Jguirim I; Najah M; Maatouk F; Varret M; Slimane MN
    Ann Clin Biochem; 2011 Jan; 48(Pt 1):83-6. PubMed ID: 21115573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia.
    Huijgen R; Fouchier SW; Denoun M; Hutten BA; Vissers MN; Lambert G; Kastelein JJP
    J Lipid Res; 2012 May; 53(5):979-983. PubMed ID: 22375030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular characterization of familial hypercholesterolemia in Spain.
    Palacios L; Grandoso L; Cuevas N; Olano-Martín E; Martinez A; Tejedor D; Stef M
    Atherosclerosis; 2012 Mar; 221(1):137-42. PubMed ID: 22244043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A new method for measurement of total plasma PCSK9: clinical applications.
    Dubuc G; Tremblay M; Paré G; Jacques H; Hamelin J; Benjannet S; Boulet L; Genest J; Bernier L; Seidah NG; Davignon J
    J Lipid Res; 2010 Jan; 51(1):140-9. PubMed ID: 19571328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study.
    Saavedra YG; Dufour R; Davignon J; Baass A
    Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2700-5. PubMed ID: 25278291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-density lipoprotein receptor activity in Epstein-Barr virus-transformed lymphocytes from heterozygotes for the D374Y mutation in the PCSK9 gene.
    Holla ØL; Cameron J; Berge KE; Kulseth MA; Ranheim T; Leren TP
    Scand J Clin Lab Invest; 2006; 66(4):317-28. PubMed ID: 16777760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel type of familial hypercholesterolemia: double heterozygous mutations in LDL receptor and LDL receptor adaptor protein 1 gene.
    Tada H; Kawashiri MA; Ohtani R; Noguchi T; Nakanishi C; Konno T; Hayashi K; Nohara A; Inazu A; Kobayashi J; Mabuchi H; Yamagishi M
    Atherosclerosis; 2011 Dec; 219(2):663-6. PubMed ID: 21872251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.